Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Positive results from Antares Pharma VIBEX MTX clinical study on RA

Antares Pharma, Inc. today announced the positive results of a clinical study evaluating VIBEX MTX, a proprietary auto injector product designed to give a rapid subcutaneous injection of methotrexate (MTX) for the treatment of rheumatoid arthritis.

5 Aug 2011

BioSante closes underwritten public offering of common stock

BioSante Pharmaceuticals, Inc. today announced the closing of its underwritten public offering of 16.0 million shares of common stock at a public offering price of $3.00 per share, for total gross proceeds of $48.0 million before underwriting discounts and commissions.

3 Aug 2011

Dangers of colon cleansing: More harm than good

According to a new study released today in the Journal of Family Practice colon cleaning may be harmful. Researchers from Georgetown University Medical School looked at 20 studies published in the last decade and found little evidence of benefit to colon cleansing. But they did find dozens of cases of problems: cramping, bloating, vomiting, electrolyte imbalance, renal failure, and even death.

1 Aug 2011

BioSante second quarter net loss increases to $15.0 million

BioSante Pharmaceuticals, Inc. today announced its financial results for the second quarter of 2011.

26 Jul 2011

BioSante announces worldwide license of Melanoma Vaccine to Hussman Foundation

BioSante Pharmaceuticals, Inc., today announced an exclusive worldwide license of its Melanoma Vaccine to The John P. Hussman Foundation, a charitable foundation that supports research to address life-threatening medical conditions and significant disabilities.

21 Jul 2011

Ventus Medical launches Provent Sleep Apnea Therapy in India

Ventus Medical is pleased to announce the Indian launch of its proprietary Provent Sleep Apnea Therapy, an innovative, non-invasive treatment for obstructive sleep apnea.

20 Jul 2011

Antares, Watson enter license deal to commercialize Anturol in the U.S. and Canada

Watson Pharmaceuticals, Inc. and Antares Pharma, Inc. today announced an exclusive licensing agreement for Watson to commercialize Antares' topical oxybutynin gel product in the U.S. and Canada.

11 Jul 2011

Poor diet, alcohol, drugs and smoking linked to sex problems

A new study published in The Journal of Sexual Medicine reveals that several unhealthy lifestyle factors, such as weight problems, physical inactivity, high alcohol consumption, tobacco smoking, and hard drugs are associated with sexual dysfunctions in men. Additionally, an unhealthy lifestyle is more common in persons who are sexually inactive.

7 Jul 2011

Unhealthy lifestyle linked to increased risk of sexual dysfunction in men

7 Jul 2011

VIVUS submits avanafil NDA to FDA for treatment of erectile dysfunction

VIVUS, Inc. today announced that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of avanafil, its investigational drug for the treatment of erectile dysfunction.

30 Jun 2011

Enrollment commences in Palatin's bremelanotide Phase 2b trial for female sexual dysfunction

Palatin Technologies, Inc. announced today that enrollment of patients has commenced in Palatin's Phase 2b clinical trial evaluating the efficacy and safety of bremelanotide (previously called PT-141), an on-demand, first-in-class melanocortin agonist being developed for the treatment of female sexual dysfunction (FSD).

28 Jun 2011

Enrollment complete in Rexahn's Serdaxin Phase IIb clinical trial for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment in its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).

22 Jun 2011

Counselling can help men overcome fears over sexual performance after prostate surgery

Men worried that prostate surgery will automatically mean an end to their sex lives are mistaken and shouldn't be put off seeking medical help, according to experts at The Prostate Centre in London.

18 Jun 2011

VIVUS Avanafil phase 3 trial on erectile dysfunction meets primary endpoints

VIVUS, Inc. today announced that the positive results from REVIVE-RP, a phase 3 clinical trial evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED),will be presented this afternoon at the 2011 Cancer Survivorship and Sexual Health Symposium in Washington D.C.

17 Jun 2011

FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

BioSante Pharmaceuticals, Inc. today announced that the FDA's clinical hold on the GVAX Prostate Cancer Vaccine for the treatment of prostate cancer has been lifted by FDA.

7 Jun 2011

Female cancer survivors benefit from natural nutritional supplement

A natural nutritional supplement, marketed for the last decade as a sexual aid, has been shown to significantly improve overall quality of life for female cancer survivors, according to researchers at Wake Forest Baptist Medical Center.

7 Jun 2011

Weight loss after bariatric surgery may reverse low testosterone, sexual dysfunction in obese men

Low testosterone levels and symptoms of male sexual dysfunction due to obesity may be reversible with weight loss after bariatric surgery, a new study finds. The results will be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

Ampio commences new anti-inflammatory agent Phase 1B trial in osteoarthritis

Ampio Pharmaceuticals, Inc. announced today that it received ethics board approval for a Phase 1B clinical trial in Australia of its biologic anti-inflammatory agent, Ampion.

1 Jun 2011

Enrollment complete in BioSante's LibiGel Phase III cardiovascular and breast cancer safety study

BioSante Pharmaceuticals, Inc., today announced completion of enrollment in its ongoing LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.

31 May 2011

Avanafil phase 3 trial in ED following radical prostatectomy meets primary endpoints

VIVUS, Inc. today announced positive results from a phase 3, placebo-controlled clinical trial of the investigational drug avanafil for the treatment of erectile dysfunction in patients following a radical prostatectomy.

25 May 2011